Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G for Maze Therapeutics Inc. Common Stock, $0.001 par value per share (MAZE).
- Disclosed ownership: 6.9%.
- Date of event: 31 Jan 2025.
Deep Track Capital, LP - 31 Jan 2025 SCHEDULE 13G Report for Maze Therapeutics Inc. Common Stock, $0.001 par value per share (MAZE)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- MAZE
- Shares outstanding
- 43,755,195 shares
- Disclosed Ownership
- 3,023,484 shares
- Ownership
- 6.9%
- Form type
- SCHEDULE 13G
- Filing time
- 07 Feb 2025, 16:30:42 UTC
- Date of event
- 31 Jan 2025
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 6.9% ownership in Maze Therapeutics Inc. Common Stock, $0.001 par value per share (MAZE) on 31 Jan 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 Feb 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 6.9% | 3,023,484 | 0 | 3,023,484 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 6.9% | 3,023,484 | 0 | 3,023,484 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 6.9% | 3,023,484 | 0 | 3,023,484 | /s/ David Kroin | David Kroin |